From Drug Benefit News - Alzheimer’s disease is ranked as one of the leading causes of death, and with a huge older U.S. population, incidence of the disease is only expected to rise. Innovation has not kept pace — but after a decade when Alzheimer’s drug development saw almost a 100% failure rate, there are now multiple drugs in late-stage clinical trials that could hit the market as early as 2018. Now the question is whether the U.S. health care system is prepared to put these innovative new treatments into practice. Read more
From Specialty Pharmacy News - One year after the FDA approved the first biosimilar drug, Zarxio (filgrastim-sndz), the Sandoz, Inc. drug is making some headway within the short-acting granulocyte colony-stimulating factor class of drugs. But there are some lessons that other biosimilar manufacturers may want to take to heart as they attempt to break into the U.S. Read more
From Specialty Pharmacy News - CMS’s recently proposed rule that would test different reimbursement tactics in Medicare Part B continues to provoke both positive and mostly negative feedback. Potentially adding fuel to the latter camp is an analysis by Avalere Health showing that the majority of the most-affected therapies are drugs to treat cancer, and many of them do not have lower-cost alternatives. Read more
Check out all of the benefits, sample issues & more!